


World Journal of *Gastrointestinal Pharmacology and Therapeutics*

World J Gastrointest Pharmacol Ther 2011 August 6; 2(4): 27-35





Editorial Board

2010-2013

The World Journal of Gastrointestinal Pharmacology and Therapeutics Editorial Board consists of 188 members, representing a team of worldwide experts in gastrointestinal pharmacology and therapeutics research. They are from 36 countries, including Australia (6), Austria (2), Belgium (2), Brazil (1), Canada (7), China (19), Czech (1), Denmark (1), Egypt (1), Estonia (1), Finland (1), France (1), Germany (5), Greece (4), Hungary (1), India (6), Iran (1), Ireland (1), Israel (3), Italy (20), Japan (17), Lithuania (1), Netherlands (6), New Zealand (1), Norway (1), Pakistan (1), Saudi Arabia (2), Singapore (2), South Africa (1), South Korea (5), Spain (7), Sweden (1), Thailand (1), Turkey (4), United Kingdom (13), and United States (41).

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Antonio Picardi, *Rome*

Elham Rahme, *Québec*

Douglas Kevin Rex, *Indianapolis*

Angelo Zullo, *Rome*

GUEST EDITORIAL BOARD MEMBERS

Full-Young Chang, *Taoyuan*

Chia-Yen Dai, *Kaohsiung*

Jiang-Huei Jeng, *Taipei*

Wun-Chang Ko, *Taipei*

Hwai Jeng Lin, *Changhua*

Tzu-Ming Pan, *Taipei*

Bor-Shyang Sheu, *Tainan*

Being-Sun Wung, *Chiayi*

MEMBERS OF THE EDITORIAL BOARD



Australia

Thomas J Borody, *Sydney*

Eline S Klaassens, *Queensland*

Ian Lawrance, *Fremantle*

A Mikocka-Walus, *Melbourne*

Tim Murphy, *Adelaide*

Neville D Yeomans, *Sydney*



Austria

Martin Brunner, *Vienna*

Michael Trauner, *Graz*



Belgium

Monika Schöller-Gyüre, *Mechelen*

Kristin Verbeke, *Alsemberg*



Brazil

Andréia Buffon, *Porto Alegre*



Canada

Brian Bressler, *Vancouver*

Grigorios I Leontiadis, *Hamilton*

Sharon Marsh, *Quebec*

Jean Sévigny, *Quebec*

Martin A Storr, *Alberta*

John T Weber, *Newfoundland*



China

Zhi-Li Huang, *Shanghai*

Bo Li, *Beijing*

Duo Li, *Shanghai*

Xue-Ying Sun, *Heilongjiang*

Ming-Fu Wang, *Hong Kong*

Rui-An Xu, *Xiamen*

Thomas Yau, *Hong Kong*

Win-Nei Yeo, *Hong Kong*

Long Yu, *Guangzhou*

Jian-Ping Yuan, *Guangzhou*

Man-Fung Yuen, *Hong Kong*



Czech

Rene Kizek, *Brno*



Denmark

Ole Haagen Nielsen, *Herlev*



Egypt

Ahmed O Abdel-Zaher, *Assiut*



Estonia

Riin Tamm, *Tartu*



Finland

Riitta Korpela, *Helsinki*



France

Frederic Batteux, *Paris*



Germany

Anton Gillissen, *Muenster*

Joachim Labenz, *Siegen*

Florian Lang, *Tübingen*

Klaus Mönkemüller, *Magdeburg*

Gerhard Treiber, *Balingen*

**Greece**

Moses Elisaf, *Ioannina*
Ioannis E Koutroubakis, *Crete*
Spilios Manolakopoulos, *Athens*
George Papatheodoridis, *Athens*

**Hungary**

Bela Molnar, *Budapest*

**India**

Mohammad S Khuroo, *Kashmir*
Mohandas K Mallath, *Mumbai*
Asish K Mukhopadhyay, *Kolkata*
Shiv Kumar Sarin, *New Delhi*
Sonu Sundd Singh, *Haryana*
Asna Urooj, *Mysore*

**Iran**

Amir M Mortazavian, *Tehran*

**Ireland**

Zaid Heetun, *Kilkenny*

**Israel**

Rami Eliakim, *Haifa*
Simon Bar Meir, *Hashomer*
Haim S Odes, *Beer Sheva*

**Italy**

Pietro Andreone, *Bologna*
Bruno Annibale, *Roma*
Giuseppe Brisinda, *Roma*
Renzo Caprilli, *Rome*
Carolina Ciacci, *Naples*
Roberto De Giorgio, *Bologna*
Alessandro Granito, *Bologna*
Pietro Invernizzi, *Rozzano*
Mariano Malaguarnera, *Catania*
Gianpiero Manes, *Milan*
Massimo C Mauri, *Milan*
Massimo Montalto, *Rome*
Giovanni Monteleone, *Rome*
Gerardo Nardone, *Napoli*
Fabio Pace, *Milan*
Rita Rezzani, *Brescia*
Carmelo Scarpignato, *Parma*
Maurizio Vecchi, *Milan*

**Japan**

Akira Andoh, *Otsu*
Norihiro Furusyo, *Fukuoka*

Susumu Ito, *Okinawa*
Satoru Kakizaki, *Gunma*
Terumi Kamisawa, *Tokyo*
Takuma Kato, *Tsu*
Takashi Kawai, *Tokyo*
Tatsuya Matsura, *Yonago*
Teruo Murakami, *Hiroshima*
Yuji Naito, *Kyoto*
Katsuyuki Nakajima, *Maebashi Gunma*
Hiroshi Nakase, *Kyoto*
Tomohiko Shimatani, *Hiroshima*
Takato Ueno, *Kurume*
Kenji Watanabe, *Osaka*
Takayuki Yamamoto, *Yokkaichi*
Norimasa Yoshida, *Kyoto*

**Lithuania**

Laimas Jonaitis, *Kaunas*

**Netherlands**

Judith E Baars, *Rotterdam*
Albert J Bredenoord, *Nieuwegein*
NKH de Boer, *Amsterdam*
PJF de Jonge, *Rotterdam*
Wouter J de Jonge, *Amsterdam*
Godefridus J Peters, *Amsterdam*

**New Zealand**

Maxim Petrov, *Auckland*

**Norway**

Reidar Fossmark, *Trondheim*

**Pakistan**

Furqaan Ahmed, *Karachi*

**Saudi Arabia**

Moamen S Refat, *Taif*
Shahab Uddin, *Riyadh*

**Singapore**

Khek-Yu Ho, *Singapore*
Kok-Yuen Ho, *Singapore*

**South Africa**

Christoffel J van Rensburg, *Cape Town*

**South Korea**

Chong-Su Cho, *Seoul*

Nayoung Kim, *Seongnam*
Kwan Sik Lee, *Seoul*
Ji-Young Park, *Seoul*
Young-Joon Surh, *Seoul*

**Spain**

Matias A Avila, *Pamplona*
Maria C Collado, *Paterna*
CM Fernandez-Rodriguez, *Madrid*
Jose JG Marin, *Salamanca*
Antonio Ruiz Medina, *Jaén*
Victor M Victor, *Valencia*
Maria D Yago, *Granada*

**Sweden**

Curt Tysk, *Örebro*

**Thailand**

Abhasnee Sobhonslidsuk, *Bangkok*

**Turkey**

Fusun Acarturk, *Ankara*
Hayrullah Derici, *Balıkesir*
Mukaddes Eşrefoğlu, *Malatya*
Ilker Tasci, *Ankara*

**United Kingdom**

Nadeem A Afzal, *Hampshire*
Qasim Aziz, *London*
Barbara Braden, *Oxford*
Susan J Duthie, *Aberdeen*
AV Emmanuel, *London*
Jin-Yong Kang, *London*
Mariusz Madalinski, *Ipswich*
John F Mayberry, *Leicester*
Chuka Uche Nwokolo, *Coventry*
Ajith K Siriwardena, *Manchester*
HH Tsai, *E Yorks*
Konstantinos Tziomalos, *London*
Craig LC Williams, *Glasgow*

**United States**

Kondala R Atkuri, *Stanford*
James M Becker, *Boston*
Qiang Cai, *Atlanta*
Liang Cheng, *Indianapolis*
Joseph John Cullen, *Iowa*
Brian J Day, *Denver*
Douglas A Drossman, *Chapel Hill*
Eli D Ehrenpreis, *Highland Park*
Bing-Liang Fang, *Houston*
Ronnie Fass, *Tucson*
S Hossein Fatem, *Minneapolis*
Linda A Feagins, *Dallas*

Lori Fischbach, *Fort Worth*
M Eric Gershwin, *Davis*
Hendrik Heinz, *Akron*
Tiberiu Herscovici, *Tucson*
Peng Huang, *Houston*
William Jeffrey Hurst, *Hershey*
Vik Khoshoo, *Marrero*
Tammy L Kindel, *Cincinnati*
Lorenzo Leggio, *Providence*
Allen W Mangel, *Research Triangle Park*
Michael F Olive, *Charleston*
Keith M Olsen, *Omaha*
Virendra N Pandey, *Newark*
Narasimham L Parinandi, *Columbus*
Paul J Pockros, *La Jolla*
Suofu Qin, *Irvine*
P Hemachandra Reddy, *Oregon*
Randolph E Regal, *Ann Arbor*
Jean-François Rossignol, *Tampa*
Leonard P Rybak, *Springfield*
George Sachs, *Los Angeles*
Bo Shen, *Cleveland*
Biographical Sketch, *Hershey*
Shi-Yong Sun, *Atlanta*
Kenneth J Vega, *Jacksonville*
Yu-Jui Yvonne Wan, *Kansas*
Jian-Min Yuan, *Minneapolis*
Jian-Ying Zhang, *El Paso*



BRIEF ARTICLES

- 27 Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers?

Zeitoun A, Zeineddine M, Dimassi H

Contents

ACKNOWLEDGMENTS I Acknowledgments to reviewers of *World Journal of Gastrointestinal Pharmacology and Therapeutics*

APPENDIX I Meetings
I-V Instructions to authors

ABOUT COVER Ali SA, Rizk MZ, Ibrahim NA, Abdallah MS, Sharara HM, Moustafa MM. Protective role of *Juniperus phoenicea* and *Cupressus sempervirens* against CCl₄. *World J Gastrointest Pharmacol Ther* 2010; 1(6): 123-131
<http://www.wjgnet.com/2150-5349/full/v1/i6/123.htm>

AIM AND SCOPE *World Journal of Gastrointestinal Pharmacology and Therapeutics* (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a bimonthly, open-access, peer-reviewed journal supported by an editorial board of 188 experts in gastrointestinal surgery from 36 countries.

The major task of *WJGPT* is to rapidly report the most recent results in basic and clinical research on gastrointestinal pharmacology and therapeutics, including the effects of drugs on the gastrointestinal, pancreatic and hepatobiliary systems, particularly with relevance to clinical practice. *WJGPT* accepts papers on the following aspects related to gastroenterology or hepatology: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, *etc.*; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial. Specifically, this journal welcome research and review articles associated with both Western medicine and Chinese herbs as well as their combinations in basic and clinical application.

FLYLEAF I-III Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Le Zhang*
Responsible Electronic Editor: *Jin-Lei Wang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Jin-Lei Wang*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL

World Journal of Gastrointestinal Pharmacology and Therapeutics

LAUNCH DATE

February 6, 2010

SPONSOR

Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

EDITING

Editorial Board of *World Journal of Gastrointestinal Pharmacology and Therapeutics*,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>

PUBLISHING

Baishideng Publishing Group Co., Limited,
Room 1701, 17/F, Henan Building,

No.90 Jaffe Road, Wanchai,
Hong Kong, China
Fax: +852-3115-8812
Telephone: +852-5804-2046
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

SUBSCRIPTION

Beijing Baishideng BioMed Scientific Co., Ltd.,
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1892
Fax: +86-10-8538-1893
E-mail: baishideng@wjgnet.com
<http://www.wjgnet.com>

PUBLICATION DATE

August 6, 2011

ISSN

ISSN 2150-5349 (online)

PRESIDENT AND EDITOR-IN-CHIEF

Lian-Sheng Ma, *Beijing*

STRATEGY ASSOCIATE EDITORS-IN-CHIEF

Antonio Picardi, *Rome*
Elham Rahme, *Quebec*
Douglas Kevin Rex, *Indianapolis*
Angelo Zullo, *Rome*

EDITORIAL OFFICE

Jin-Lei Wang, Director
World Journal of Gastrointestinal Pharmacology and Therapeutics
Room 903, Building D, Ocean International Center,
No. 62 Dongsihuan Zhonglu, Chaoyang District,
Beijing 100025, China
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>

COPYRIGHT

© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at http://www.wjgnet.com/2150-5349/g_info_20100315084234.htm.

ONLINE SUBMISSION

<http://www.wjgnet.com/2150-5349office>

Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers?

Abeer Zeitoun, Maya Zeineddine, Hani Dimassi

Abeer Zeitoun, Maya Zeineddine, Hani Dimassi, Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, PO Box 36, Byblos, Lebanon

Author contributions: Zeitoun A designed the study, created the data collection form, was involved in data analysis and was responsible for writing the manuscript; Zeineddine M was responsible for supervising data collection, performing data entry and revising the manuscript; Dimassi H performed the statistical analysis and wrote up the results.

Correspondence to: Abeer A Zeitoun, Pharm D, Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, PO Box 36, Mail Box: F74, Byblos, Lebanon. abeer.zeitoun@lau.edu.lb

Telephone: +961-9-547254-2419 Fax: +961-9-547256

Received: January 23, 2011 Revised: July 11, 2011

Accepted: July 18, 2011

Published online: August 6, 2011

CONCLUSION: This study highlighted the need, in Lebanese hospitals, to establish clinical practice guidelines for the use of SUP; mainly in non-critical care settings.

© 2011 Baishideng. All rights reserved.

Key words: Stress ulcer prophylaxis; Lebanese hospitals; Proton-pump inhibitors; Histamine 2 receptor antagonists; American Society of Health-System Pharmacists guidelines

Peer reviewer: Ole Haagen Nielsen, Professor, Chief Physician, Department of Gastroenterology, Medical Section D112M, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark

Zeitoun A, Zeineddine M, Dimassi H. Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers? *World J Gastrointest Pharmacol Ther* 2011; 2(4): 27-35 Available from: URL: <http://www.wjgnet.com/2150-5349/full/v2/i4/27.htm> DOI: <http://dx.doi.org/10.4292/wjgpt.v2.i4.27>

Abstract

AIM: To evaluate the current practice of stress ulcer prophylaxis (SUP) in Lebanese Health care centers.

METHODS: A multi-center prospective chart review study was conducted over 8 mo. A questionnaire was distributed to pharmacy students who collected data on demographics, SUP medications, dose, route, duration and associated risk factors. The appropriateness of SUP use was determined as per American Society of Health-System Pharmacists guidelines. Institutional review board approval was obtained from each hospital center.

RESULTS: A total of 1004 patients were included. 67% of the patients who received prophylaxis did not have an indication for SUP. The majority (71.6%) of the patients who were administered parenteral drugs can tolerate oral medications. Overall, the regimen of acid-suppressant drugs was suboptimal in 87.6% of the sample. This misuse was mainly observed in non-teaching hospitals.

INTRODUCTION

Stress ulcers are single or multiple gastroduodenal mucosal defects that cause a broad range of clinical manifestations from superficial mucosal erosions or mild-severe ulceration to life-threatening bleeding^[1,2]. When patients are hospitalized, the risk of stress ulcers increases. This is particularly true for patients admitted to intensive care settings following the physiologic stress of serious illness such as surgery or trauma^[2]. Within 24 h of admission to the intensive care unit (ICU), endoscopic evidence of stress-related mucosal disease (SRMD) was documented in 75% to 100% of critically ill patients^[3]. Although mucosal erosions may be of little clinical significance because of rapid healing, they cannot be ignored. Stress ulcers present a risk of clinically important bleeding,

which is associated with hemodynamic instability, such as hypotension, tachycardia or respiratory failure, or results in anemia or the need for transfusion^[3].

Clinically significant bleeding occurs in approximately 1% to 4% of critically ill patients with a mortality rate that approaches 50%^[3,4].

The pathophysiology of SRMD is unclear but probably is related to a reduction in mucosal blood flow or a breakdown in other normal mucosal defense mechanisms in conjunction with the injurious effects of acid and pepsin on the gastroduodenal mucosa^[5]. Since acid does appear to be involved in the pathogenesis of these lesions, acid-suppressive regimens have the potential to prevent SRMD^[5-7].

Treatment of stress ulceration usually begins with prevention. Several consensus guidelines for stress ulcer prophylaxis (SUP) have been published^[8-10]. The most recent guidelines available on SUP were published by The American Society of Health-System Pharmacists (ASHP) in 1999^[9]. These guidelines provide evidence-based recommendations for the practice of SUP in non-critically ill medical and surgical patients, critically ill patients and ICU pediatric populations^[9] (Table 1). Although little evidence supports its use^[11,12], acid-suppressive therapy (AST) is largely prescribed in hospitalized patients.

Several studies evaluated the practice pattern of SUP in American and European healthcare centers^[12-16]. Gullotta *et al.*^[12], in a multicenter cohort study at an Italian hospital, showed that 51.4% of hospitalized patients received inappropriate prescription of AST. Similarly, Scagliarini *et al.*^[15] found that AST was overused in hospital settings with the main reason for inadequate prescriptions being ulcer-prophylaxis in low-risk patients. Moreover, Pham *et al.*^[16], in a retrospective chart review study at the University of Michigan Hospital, demonstrated that only 10 % of the patients receiving acid suppressants were found to have an acceptable indication. This highlighted the need for the implementation of practice guidelines and selection criteria to avoid excessive and unmotivated use of AST. However, there are insufficient data in the literature to describe the appropriateness of SUP use in healthcare centers in the Middle East region.

Therefore, the extent to which SUP guidelines are implemented in Lebanese healthcare centers needs to be further assessed and discussed. The following study is an effort to evaluate the appropriateness of SUP practice in a number of Lebanese hospitals from different regions of the country. Our objective was to assess SUP practice in terms of proper indication, drug choice, dose, route of administration and duration of prophylaxis.

MATERIALS AND METHODS

Design, setting and sample selection

This medication use evaluation (MUE) study, conducted between July 2009 and February 2010, used a multicenter prospective design, where centers from all parts of Lebanon were selected for data collection. Sixteen hos-

pitals participated in this study. The institutional review board of each hospital granted approval for the study. To facilitate data analysis, the hospitals were divided into six teaching hospitals and ten non-teaching hospitals. The data collection extended over a period of 8 mo. Pharmacy students at the Lebanese American University School of pharmacy, on rotation at the selected hospitals, were in charge of data collection. Each student was instructed to select and follow up twenty newly admitted patients from the following services; internal medicine (IM), ICU, critical care unit (CCU), surgery, obstetrics and gynecology, and pediatrics.

Patients were excluded from data collection if they had one of the following: (1) a history of active gastrointestinal (GI) ulceration or bleeding of a duration of more than 1 year; (2) an active GI bleeding or an active peptic, gastric or duodenal ulcer at the time of admission or during their hospital stay; (3) are using non steroidal anti-inflammatory drugs (NSAID) treatment at home or in the hospital; or (4) were taking any acid suppressive therapy as home medication. All other patients, receiving acid suppression therapy for SUP, were considered eligible for this study.

A pharm D candidate reviewed the collected data on weekly basis as part of her pharmD project. The pharm D student's responsibility was to supervise patient selection and data abstraction. One thousand six hundred and ninety charts were reviewed; 1004 patients covering different units such as IM, ICU, CCU, surgery, and others were included in the study. Subsequently, patients were then classified as candidates or non-candidates for SUP based on ASHP criteria (Table 1).

Data collection

A special data sheet was created, for medical chart data abstraction, which included the following eight sections: (1) Patient's demographics: general characteristics of the patients such as age, gender, unit, length of hospital stay and allergies. These data are important to assess patients' risks for SUP^[8,9,17,18]; (2) Disease state: including chief complaint, history of present illness, diagnosis and prescribed medications. These data are crucial to check for the eligibility of the patients to the study^[9,19,20]; (3) SUP regimen (agents used, dose, route, frequency, and duration) in addition the discharge medications were listed to allow the assessment of SUP appropriateness^[14,21,22]. According to ASHP guidelines on SUP, histamine 2 antagonists (H2-RAs), antacids, and sucralfate are recommended for the prevention of stress ulcers. The choice of the drug is institution-specific^[9,23-27] and should take into account concerns regarding ease of administration, adverse events and cost^[14,26,28]. When the ASHP guidelines were published, there was insufficient data available on the efficacy and safety of misoprostol and proton pump inhibitors (PPIs) to allow their recommendation. However, multiple studies examined the effects of PPIs in reducing SRMD-related bleeding, but all were either small or observational with PPI as the only treatment arm^[29].

Table 1 American Society of Health-System Pharmacists recommendations for stress ulcer prophylaxis

Population	Treatment recommendations	Grade
Non-critically ill medical and surgical patients	Prophylaxis not recommended	B ¹
Critically ill patients with one of the following:		
Coagulopathy (i.e. platelet count of < 50 000 mm ³ , INR of 1.5)	Prophylaxis recommended	C
Mechanical ventilation for > 48 h		C
History of gastrointestinal ulceration or bleeding within 1 year of admission		D
Glasgow Coma score of ≤ 10		B, D ²
Thermal injury to > 35% of body surface area		B, D ³
Partial hepatectomy		C, D ⁴
Multiple trauma (injury severity score of ≥ 16)		D
Hepatic or renal transplantation		D
Spinal cord injury		D
Hepatic failure		D
Two or more of the following risk factors: sepsis, ICU stay of greater than 1 wk, occult bleeding lasting at least 6 d, and high-dose corticosteroids (> 250 mg/d of hydrocortisone or equivalent daily)		D
Pediatric patients with one of the following:		
Respiratory failure	Prophylaxis recommended	C
Coagulopathy		C
Pediatric Risk of Mortality Score of ≥ 10		C
Thermal injuries		D

¹Strength of evidence = B for general medical and surgical patients with fewer than two risk factors for clinically important bleeding; strength of evidence = D for patients with two or more risk factors; ²Strength of evidence = B for histamine H₂-receptor antagonist (H₂-RAs); strength of evidence = D for antacids and sucralfate; ³Strength of evidence = B for antacids; strength of evidence = D for H₂-RAs and sucralfate; ⁴Strength of evidence = C for H₂-RAs; strength of evidence = D antacids and sucralfate. INR: International normalized ratio; ICU: Intensive care unit.

Similarly, the small patient populations limit the results of comparative studies (PPIs *vs* placebo or H₂-RAs)^[30-32]. Data available indicate that PPIs are safe and efficacious for SUP^[7,32-34]. However, PPIs should be used only as an alternative to H₂-RAs or sucralfate pending further comparative studies with large sample size and pharmacoeconomic analysis^[29-34]. As for misoprostol, the profile of side effects, drug interactions, lack of overall efficacy and availability of alternatives preclude its use in current medical practice^[35]. To sum up, options for prophylaxis include antacids, H₂-RAs, sucralfate and PPIs. In order to evaluate the adequacy of dosing these agents, a review of the literature was needed to extract the recommended doses since most of the medications used for SUP are not FDA approved for this indication (Table 2)^[9,35,36]. Thus, a prescribed dose was considered correct if it coincides with the extrapolated doses. The route of administration (oral or parenteral) was also recorded. Regarding the duration of prophylaxis, the ASHP guidelines recommend discontinuing the prophylaxis once the risk factors are resolved^[9,19]. Therefore, the duration of the prophylaxis and the discharge medications were documented to assess guideline compliance; (4) Past medical history/ Past medical treatment: This section of the data sheet identified the patients to be excluded. It mainly recognized patients with a history of GI ulceration or bleeding, patients on AST for the treatment of GI disease (gastroesophageal reflux disease, eosophagitis *etc.*) or patients on chronic NASID therapy. Those patients were not included in our study since it is not known if a history of GI ulcerations and bleeding increases the risk of acute stress-induced bleeding^[8,9]. Similarly, NSAIDs were not thoroughly studied as risk factors for stress ulcers although their long-

Table 2 Dosage regimens for agents used for stress ulcer prophylaxis

Medication	Adult range
Cimetidine	300 mg <i>qid</i> po, NG, or iv or 50 mg/h by continuous iv infusion
Famotidine	20 mg <i>bid</i> po, NG, or iv or 1.7 mg/h by continuous iv infusion
Ranitidine	150 mg <i>bid</i> po or NG, 50 mg every 6-8 h iv, or 6.25 mg/h by continuous iv infusion
Nizatidine	150 mg <i>bid</i> po or NG
Antacids	30-60 mL po or NG every 1-2 h
Sucralfate	1 g <i>qid</i> po or NG
Omeprazole	40 mg LD then 20-40 mg daily po, NG or iv
Lansoprazole	30 mg daily po, NG or iv
Esomeprazole	20-40 mg daily po, NG or iv
Rabeprazole	20 mg daily po or NG
Pantoprazole	40 mg daily po or NG or iv

LD: Loading dose; NG: Nasogastric tube.

term use was associated with GI bleeding problems^[37-39]; (5) Current GI bleeding: Patients with active GI bleeding were also excluded from the study since those patients will be receiving AST as a pharmacologic intervention for the management of upper GI bleeding. Moreover, prophylaxis has no role and is not indicated in this population^[40-42]; (6) Lab tests including complete blood count, liver function tests and stool exam were documented to monitor for bleeding^[43-45]; (7) Stress ulcers risk factors: A stress ulcer risk stratification, adopted from the ASHP guidelines, divided patients into three categories: non-critically ill medical patients, ICU populations and pediatrics. The recommendation for prophylaxis was based on the risk factors for clinically important bleeding. According

to the ASHP guidelines, SUP is not recommended for non-critically ill patients with fewer than two risk factors for clinically significant bleeding^[8,9,19]. As for the ICU population, prophylaxis is recommended in (a) patients with coagulopathy; (b) patients requiring mechanical ventilation for more than 48 h; (c) patients with a history of GI ulceration or bleeding within 1 year before admission; and (d) patients with at least two of the following risk factors: sepsis, ICU stay of more than 1 wk, occult bleeding lasting 6 d or more, and use of high-dose corticosteroids (> 250 mg/d of hydrocortisone or the equivalent)^[9]. Moreover, special ICU populations such as patients with a Glasgow Coma Score of ≤ 10 or thermal injuries to $> 35\%$ of their body surface area, and so forth, may benefit from prophylaxis (Table 1). For pediatrics, patients with any risk factor for clinically important bleeding (respiratory failure, coagulopathy, and a Pediatric Risk of Mortality Score of ≥ 10) or patients with thermal injuries are candidate for SUP^[9]. Therefore, we subdivided our study populations into three groups (non-ICU, ICU and pediatric populations) to evaluate the SUP appropriateness per ASHP guidelines; and (8) The route of administration of AST, being oral or parenteral, was recorded in this section since parenteral therapy should only be used when the oral therapy is not tolerated^[46,47]. To identify the patients who can tolerate oral medications, the routes of administration of other prescribed medications were also reported.

Data analysis

Abstracted data were coded and entered into the SPSS version 18 for analysis. Summary statistics, including frequency percent means and standard deviations were calculated to summarize the data. Differences in proportions were tested using the Pearson chi-square when assumptions were met; if not, the Fisher's exact test was used. Differences in the hospital duration stay were tested using the Mann-Whitney non-parametric test. Practice of SUP was classified as either appropriate or inappropriate taking into consideration the indication for SUP, agents used, route, dose, frequency and the duration of the prophylaxis. In addition, SUP practice was compared across different patient populations (non-ICU, ICU and pediatrics) and hospital type (teaching *vs* non-teaching). All analyzes were carried out at the 0.05 significance level.

RESULTS

A total of 1690 surveys were completed; of which 1004 were eligible for enrollment in the study. The mean age was 54.6 ± 21.2 and the gender distribution was 52.5% males and 47.5% females. The surveys were collected from sixteen different Lebanese hospitals across the country. The mean number of surveys filled per hospital site was 63 (range: 13-172). The 1004 patients were divided among different hospital units: 236 (23.5%) were from critical care units (ICU and CCU), 728 (72.5%) were from other units, whereas the remaining 40 (4.0%)

Table 3 General characteristics of the sample ($n = 1004$)

Patients characteristics	<i>n</i> (%)
Gender	
Males	527 (52.5)
Females	477 (47.5)
Age (yr, mean \pm SD)	54.6 \pm 21.2
Unit	
ICU	142 (14.1)
IM	468 (46.6)
Surgery	190 (18.9)
CCU	94 (9.4)
Pediatrics	40 (4.0)
OBGYN	28 (2.8)
Others	42 (4.2)
Hospital stay: Median and IQR (d)	4.0 (5.0) ¹
Acid-suppressant drugs	
PPIs	618 (61.6)
Omeprazole	477 (47.5)
Lansoprazole	50 (5.0)
Esomeprazole	5 (0.5)
Rabeprazole	86 (8.6)
H2-RAs	386 (38.4)
Ranitidine	384 (38.2)
Nizatidine	2 (0.20)
Duplicate therapy	0 (0)

¹The median was reported since this variable was positively skewed. ICU: Intensive care unit; IM: Internal medicine; CCU: Critical care unit; OBGYN: Obstetrics and gynecology; IQR: InterQuartile range; PPIs: Proton-pump inhibitors; H2-RAs: Histamine 2 receptor antagonist.

were from the pediatric unit (Table 3). Since the length of hospitalization is critical to determine the duration of the prophylaxis, hospital stay was also assessed, and the median hospital stay was found to be 4 d. Of the 1004 patients, 618 (61.6%) received PPIs of which omeprazole was the most commonly used (477 out of 618), and 386 (38.4%) received H2-RAs of which ranitidine was the most commonly prescribed (384 out of 386). Moreover, PPIs were administered orally in 48.4% of the patients, whereas oral H2-RAs were given in only 5.2% of the patients ($P < 0.001$).

The SUP was classified as either appropriate or inappropriate according to the ASHP guidelines (Table 1). Of 1004 patients receiving AST, 67% ($n = 673$) did not have an indication for SUP according to our ASHP-based guidelines. 771 (76.8%) patients were administered the drug parenterally, of which 551 (71.6%) patients were able to tolerate the oral route. Although 89% of the patients received the appropriate dose, overall, only 12.4 % of the sample population was candidate for SUP and was administered the acid-suppressive regimen (dose, frequency and route) appropriately (Table 4).

The practice pattern of SUP was further analyzed by comparing each component of the AST (drug class, dose, frequency, route and duration) in patients who were candidate for prophylaxis *vs* those who were not. There was no statistically significant difference in the prescription of PPIs between the two groups: 62.8% of patients who had an indication for SUP and 60.9% of patients who did not, were on PPI ($P = 0.557$) (Table 5). Moreover, the

Table 4 Assessment of stress ulcer prophylaxis practice

SUP variable	n (%)
Indication	
Non-Candidates for SUP ¹	673 (67)
Candidates for SUP ²	331 (33)
1 major risk factor ³	53 (25.2)
2 minor risk factors ⁴	204 (20.3)
7 d stay in ICU and 1 minor risk factor	38 (3.8)
Dose	
Appropriate	891 (88.9)
Inappropriate	111 (11.1)
Route	
Oral	232 (23.2)
Parenteral	770 (76.8)
Inappropriate ⁵	551 (71.6)
Duration (d)	
Median (IQR)	4.0 (5) ⁶
Regimen (dose + route + duration)	
Appropriate	124 (12.4)
Inappropriate	880 (87.6)

¹Non-candidates are patients receiving stress ulcer prophylaxis (SUP) without an appropriate indication; ²Candidates are patients receiving SUP with an appropriate indication according to American Society of Health-System Pharmacists guidelines; ³Major risk factors are: coagulopathy, mechanical ventilation > 48 h or history of gastrointestinal ulceration or bleeding within 1 year of admission; ⁴Minor risk factors are all other risk factors listed in Table 1; ⁵Inappropriate route is defined as the use of parenteral drugs when oral drugs can be tolerated; ⁶The median was reported since this variable was positively skewed. ICU: Intensive care unit; IQR: Interquartile range.

majority of patients in both groups received omeprazole as PPI and ranitidine as H2-RAs. Inappropriate dosing was defined as receiving doses that did not coincide with the tabulated doses (Table 2). Appropriate dosing was observed in 84.9% of the candidates for SUP and in 90% of the patients who did not have a justified indication for SUP ($P = 0.004$). Duration of prophylaxis was 5 d in the “candidates” group compared to 3 d in the “non-candidates” group ($P < 0.001$). For further evaluation of the duration of the prophylaxis, the discharge medications were also assessed. A discharge plan was missing in 499 out of 1004 surveys. Of the 505 available surveys, 119 (23.6%) patients were discharged on SUP and 386 (76.4%) patients were not. The majority of patients for which SUP was indicated were discharged on AST (28.8% in the “candidates” group *vs* 20.9% in the “non-candidates” group, $P = 0.047$) (Table 5).

The appropriateness of SUP was further assessed within teaching and non-teaching hospitals. The sample was divided into two groups resulting in 405 (40.3%) patients from teaching hospitals and 599 (59.7%) patients from non-teaching hospitals. 37.8% and 28.7% of the patients who receive AST in teaching and non-teaching hospitals respectively had an indication for SUP ($P = 0.008$). Furthermore, there was a statistically significant difference in the adequacy of dosing acid-suppressants between teaching hospitals (86.4% appropriate dosing) and non-teaching hospitals (90.6% appropriate dosing, $P = 0.038$). However, overall dosing practice (dose and

Table 5 Assessment of stress ulcer prophylaxis practice per indication n (%)

SUP variable	Candidates	Non-candidates	P-value
Acid-suppressant drugs			
PPIs	208 (62.8)	410 (60.9)	0.557
H2-RAs	123 (37.2)	263 (39.1)	
Dose			
Appropriate	281 (84.9)	610 (90.0)	0.004
Inappropriate	50 (15.1)	61 (9.1)	
Route			
Appropriate	150 (45.3)	301 (44.7)	0.859
Inappropriate	181 (54.7)	372 (55.3)	
Dose and route			
Appropriate	124 (37.5)	265 (39.4)	0.558
Inappropriate	207 (62.5)	408 (60.6)	
Duration (d)			
Median (IQR)	5.0 (7.0)	3.0 (4.0)	< 0.001 ¹
Discharge on SUP			
Yes	49 (28.8)	70 (20.9)	0.047
No	121 (71.2)	265 (79.1)	

¹P-value derived using the Mann-Whitney *U* test; P-value remained significant even after controlling for hospital stay. SUP: Stress ulcer prophylaxis; PPIs: Proton pump inhibitors; H2-RAs: Histamine 2 receptors antagonists; IQR: Interquartile range.

route) was more adequate in teaching hospitals than in non-teaching hospitals (44% *vs* 35.2% respectively, $P = 0.005$). This significant difference in appropriate dosing was only detected when the drug was administered parenterally (93.1% *vs* 84.9% in teaching and non-teaching hospitals respectively, $P < 0.001$). PPIs were more frequently used in teaching hospitals compared to non-teaching hospitals (65.7% *vs* 58.8%, $P = 0.027$). Patients from teaching hospitals tended to receive SUP for a longer duration (5 d *vs* 3 d in non-teaching hospitals, $P < 0.001$).

The difference between hospital types according to candidate status was also assessed. Furthermore, SUP practice was analyzed by looking at its appropriateness by both indication and hospital type (Table 6).

DISCUSSION

This study assessed real-world dosing practices in 1004 hospitalized patients, in sixteen Lebanese hospitals, using a multi-center survey method. Hospitals from all regions of the country were selected to maximize the generalizability of the results. Our results showed that only 33% of Lebanese inpatients were prescribed AST in accordance with the ASHP guidelines for SUP. Therefore, 67% of hospitalized patients received unjustified prophylaxis. The fact that the majority of the patients who were on SUP therapy were non-critically ill medical and surgical patients raises major concern.

According to the ASHP guidelines, SUP is not recommended for general medical and surgical patients in non-ICU settings with fewer than two risk factors for clinically important bleeding, or for patients with two or more risk factors (Table 1). Few studies^[12,47-49] to date have effectively examined the role of SUP in non-ICU patients.

Table 6 Assessment of stress ulcer prophylaxis practice per hospital type *n* (%)

SUP variable	Teaching	Non-teaching	P-value
Indication			
Candidates	153 (37.8)	178 (29.7)	0.008
Non-candidates	252 (62.2)	421 (70.3)	
Dose			
Appropriate	350 (86.4)	541 (90.6)	0.038
Inappropriate	55 (13.6)	56 (9.4)	
Route			
Appropriate	206 (50.9)	245 (40.9)	0.002
Inappropriate	199 (49.1)	354 (59.1)	
Dose and route			
Appropriate	178 (44.0)	211 (35.2)	0.005
Inappropriate	227 (56.0)	388 (64.8)	
Acid-suppressant drugs			
PPIs	266 (65.7)	352 (58.8)	0.027
H2-RAs	139 (34.3)	247 (41.2)	
Duration (d)			
Median (IQR) ¹	5 (10)	3 (3.75)	< 0.001 ¹
Discharge on SUP			
Yes	53 (26.2)	66 (21.8)	0.248
No	149 (73.8)	237 (78.2)	

¹P-value lost significance when controlling for hospital stay. SUP: Stress ulcer prophylaxis; PPIs: Proton pump inhibitors; H2-RAs: Histamine 2 receptors antagonists; IQR: Interquartile range.

Qadeer *et al.*^[49], in a retrospective case-control study at an American tertiary care center (*n* = 17 707 patients), demonstrated that hospital-acquired bleeding is uncommon in non-critically ill patients, thus, routine prophylaxis is unnecessary in most hospitalized patients. Moreover, a second retrospective study done by Heidelbaugh *et al.*^[47] showed that SUP in the non-ICU setting results in significant cost expenditures without beneficial impact on the quality of care. These results, taken together with the results of our study, highlight the need to establish well-defined risk factors for stress ulcers and implement appropriate prevention strategies in the non-ICU setting.

Concerning the choice of the acid-suppressive agent, PPIs and H2-RAs were the only drug classes prescribed in our study, with a higher frequency use of PPIs. The ASHP recommends antacids, H2-RAs and sucralfate as options for prophylaxis. In a meta-analysis by Cook *et al.*^[25], various prophylactic therapies, including antacids, sucralfate, and H2-RAs, were found to reduce the incidence of clinically important bleeding compared with no prophylaxis. However, antacids are no longer considered a viable therapeutic option because of the labor-intensive dosing frequency and potential side effects^[33]. Another option is sucralfate: a meta-analysis^[27] assessing the efficacy of sucralfate compared with H2RAs (nine studies) and antacids (eight studies) for the prophylaxis of stress ulcers indicated that sucralfate was at least as effective as the other agents. Nevertheless, sucralfate is not available on the Lebanese pharmaceutical market.

Although H2-RAs are the most widely used drugs for SUP worldwide^[17], its use was overwhelmed by the prescription of PPIs in Lebanese hospitals. This can be

explained by the following: (1) Tolerance to H2-RAs acid inhibition develops as early as 72 h after administration; (2) PPIs are the most potent antisecretory agents available; (3) PPIs are at least as effective as H2-RAs in SUP; (4) PPIs can be administered through a nasogastric tube or jejunum or parenterally when oral medication is not tolerated; and (5) PPIs are well-tolerated with a low incidence of adverse effects^[33,50,51].

Overall, 11.1% of the Lebanese inpatients received incorrect doses and SUP was indicated in the majority of them. This is predictable because recommendations are lacking for prophylactic dosing of most acid-suppressive agents. Only cimetidine, sucralfate and the powder suspension of omeprazole are FDA approved for SUP indication^[10,52,53].

Furthermore, the route of administration was inadequate in the majority of the patients: 70% of the patients who were receiving parenteral drugs can tolerate oral medications. Our study suggests that the inadequacy in administering the drugs is due to the misconception that parenteral medications are more effective than oral ones. However, studies^[54-56] failed to show any efficacy or safety advantages of one formulation over the other. Thus, to minimize the potential adverse effects and additional costs of parenteral administration^[9,54-56] the parenteral route should be reserved for patients who cannot tolerate oral medications.

The median hospital stay and the median duration of SUP coincide. Further comparison showed that patients who have an acceptable indication for SUP were maintained on the prophylaxis for longer than the “non-candidate” group. These results are expected since prophylaxis should be discontinued upon discharge from the hospital or until the resolution of risk factors^[9]. Nevertheless, a large number of patients (*n* = 120), mainly in the “candidates” group, was discharged on AST. This practice is unjustified, and there is no evidence-based data that support the continuation of AST at discharge^[57,58]. Furthermore, long-term use of acid-suppression medications was associated with an increase in unnecessary expenses^[47,57], and most importantly with an increased risk of pneumonia^[59], hip fracture^[60] and *Clostridium difficile* colitis^[61,62].

In order to explore whether teaching hospitals are more compliant with SUP guidelines, patients were stratified into two groups, resulting in statistically significant differences: a higher proportion of inpatients in teaching healthcare centers received adequate prophylaxis compared to patients in non-teaching hospitals. Therefore, SUP was significantly better practised in teaching hospitals. Such results are not surprising because teaching hospitals are more likely to follow guidelines and recommendations^[63,64].

This study reinforces the results of previous studies undertaken in the Middle East. Recently, Khudair *et al.*^[65], in a MUE study conducted at Hamad General Hospital in Qatar (389 patients) assessing the prescribing pattern of acid-suppressive medications in medical inpatients, found that the usage of SUP was unjustified in 66% of patients.

Moreover, a second observational study by Mayet^[66] ($n = 661$) was carried out at King Khalid University Hospital, a tertiary teaching hospital in Saudi Arabia. Its objective was to evaluate the improper use of pantoprazole and ranitidine. The results showed that improper use of these medications was observed in 43% of the patients, emphasizing the need to implement practice guidelines in order to reduce the misuse of AST^[66].

Although our study was limited to Lebanese healthcare centers, its results can serve as a base for national and international future clinical studies. Indeed, SUP is a wide practice in medicine worldwide. The current practice of SUP may vary among countries as well as various hospitals in the same country; yet comparing this variability between different clinical settings may help in the establishment of clear, well-defined clinical practice guidelines for the prevention of stress ulcers, specifically in the non-critical care settings.

This study has a number of limitations. Missing data was a major limitation, especially information about the continuation of SUP after discharge, which was lacking in half the sample. Secondly, the correlation between appropriate SUP practice and clinical outcomes, in terms of safety and efficacy of AST, were not assessed in our study. Thirdly, although pharm D students were auditing and precepting the process of data collection, the chance for inter-rater variation and inconsistency still exists since data abstraction was carried out by 60 different pharmacy students.

There are also several strengths in this study that should also be addressed. Firstly, the inclusion of sixteen hospitals from different geographical areas increases the external validity of the study, making it better representative of the population. Secondly, the number of patients recruited was large which increases the power of the study. Thirdly, this study, evaluating the practice pattern of SUP in Lebanese healthcare centers is the first of its kind in Lebanon. Moreover, the study evaluated the appropriateness of prophylaxis in three different populations and was not limited to critically ill patients. Finally, a biostatistician was consulted, which increases the accuracy of our results.

In conclusion, this study assessed the appropriateness of SUP practice in correlation with the only available guideline, the ASHP guidelines. Lebanon suffers from widespread suboptimal practice of SUP in hospital practice. The results of this study highlight the need for the implementation of correction measures and practice guidelines in critical care as well as non-critical care settings. More awareness and education should be considered in Lebanese hospitals, especially in non-teaching sites where the practice of evidence-based medicine may be minimal. In the absence of firm recommendations, the non-critically ill population requires additional attention. This can be achieved by: (1) clearly defining the risk factors for clinically significant bleeding in this population; and (2) periodically monitoring the practice pattern of SUP to further minimize its overuse in non-critically

ill patients.

COMMENTS

Background

The incidence of stress ulcers increases when patients are hospitalized. Progression of stress ulcers to clinically important bleeding is associated with a mortality rate of approximately 50%.

Research frontiers

Since acid may be involved in the pathogenesis of stress-related ulcerations, acid suppressive regimens have been shown to prevent these lesions; and consensus guidelines for stress ulcer prophylaxis (SUP) have been published by The American Society of Health-System Pharmacists. However, the way SUP guidelines are implemented in Lebanese healthcare centers has not been unequivocally addressed. In this study, the authors evaluate the practice of SUP in Lebanese healthcare centers to improve the effectiveness of acid suppressive therapy on preventing stress ulcers, and simultaneously reducing adverse reactions.

Innovations and breakthroughs

Several studies demonstrated that acid suppressive therapy is inappropriately prescribed in American and European hospitals. This is the first study that assesses the SUP practice in Lebanese health care centers.

Applications

The study results highlight the need for the implementation of SUP practice guidelines in Lebanese hospitals, particularly in the non-critical areas where firm recommendations are still lacking.

Peer review

The authors examined the use of SUP in a multicenter study of sixteen Lebanese hospitals. It revealed that in the majority of the patients, acid suppressive therapy was administered without any scientific evidence. The results are interesting and may be applied to many other countries (than Lebanon) world-wide.

REFERENCES

- 1 **Mutlu GM**, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. *Chest* 2001; **119**: 1222-1241
- 2 **Anderberg B**, Sjö Dahl R. Prophylaxis and management of stress ulcers. *Scand J Gastroenterol Suppl* 1985; **110**: 101-104
- 3 **Fennerty MB**. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. *Crit Care Med* 2002; **30**: S351-S355
- 4 **Ben-Menachem T**, McCarthy BD, Fogel R, Schiffman RM, Patel RV, Zarowitz BJ, Nerenz DR, Bresalier RS. Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. *Crit Care Med* 1996; **24**: 338-345
- 5 **Cho CH**, Koo MW, Garg GP, Ogle CW. Stress-induced gastric ulceration: its aetiology and clinical implications. *Scand J Gastroenterol* 1992; **27**: 257-262
- 6 **Cook DJ**, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. *N Engl J Med* 1994; **330**: 377-381
- 7 **Martindale RG**. Contemporary strategies for the prevention of stress-related mucosal bleeding. *Am J Health Syst Pharm* 2005; **62**: S11-S17
- 8 **Tryba M**, Cook D. Current guidelines on stress ulcer prophylaxis. *Drugs* 1997; **54**: 581-596
- 9 ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. *Am J Health Syst Pharm* 1999; **56**: 347-379
- 10 **Wilcox CM**, Spenney JG. Stress ulcer prophylaxis in medical patients: who, what, and how much? *Am J Gastroenterol* 1988; **83**: 1199-1211
- 11 **Grau JM**, Casademont J, Fernández-Solá J, Cardellach F, Urbano-Márquez A. Prophylaxis of gastrointestinal tract bleeding in patients admitted to a general hospital ward.

- Comparative study of sucralfate and cimetidine. *Scand J Gastroenterol* 1993; **28**: 244-248
- 12 **Gullotta R**, Ferraris L, Cortelezzi C, Minoli G, Prada A, Comin U, Rocca F, Ferrara A, Curzio M. Are we correctly using the inhibitors of gastric acid secretion and cytoprotective drugs? Results of a multicentre study. *Ital J Gastroenterol Hepatol* 1997; **29**: 325-329
- 13 **Nardino RJ**, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. *Am J Gastroenterol* 2000; **95**: 3118-3122
- 14 **Parente F**, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, Bianchi Porro G. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. *Aliment Pharmacol Ther* 2003; **17**: 1503-1506
- 15 **Scagliarini R**, Magnani E, Praticò A, Bocchini R, Sambo P, Pazzi P. Inadequate use of acid-suppressive therapy in hospitalized patients and its implications for general practice. *Dig Dis Sci* 2005; **50**: 2307-2311
- 16 **Pham CQ**, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. *Ann Pharmacother* 2006; **40**: 1261-1266
- 17 **Spirit MJ**, Stanley S. Update on stress ulcer prophylaxis in critically ill patients. *Crit Care Nurse* 2006; **26**: 18-20, 22-28; quiz 29
- 18 **Simons RK**, Hoyt DB, Winchell RJ, Holbrook T, Eastman AB. A risk analysis of stress ulceration after trauma. *J Trauma* 1995; **39**: 289-293; discussion 293-294
- 19 **Grube RR**, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. *Am J Health Syst Pharm* 2007; **64**: 1396-1400
- 20 **Allen ME**, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. *Am J Health Syst Pharm* 2004; **61**: 588-596
- 21 **Erstad BL**, Barletta JF, Jacobi J, Killian AD, Kramer KM, Martin SJ. Survey of stress ulcer prophylaxis. *Crit Care* 1999; **3**: 145-149
- 22 **Lam NP**, Lê PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. *Crit Care Med* 1999; **27**: 98-103
- 23 **Cook D**, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. *N Engl J Med* 1998; **338**: 791-797
- 24 **Kingsley AN**. Prophylaxis for acute stress ulcers. Antacids or cimetidine. *Am Surg* 1985; **51**: 545-547
- 25 **Cook DJ**, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. *JAMA* 1996; **275**: 308-314
- 26 **Messori A**, Trippoli S, Vaiani M, Gorini M, Corrado A. Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. *BMJ* 2000; **321**: 1103-1106
- 27 **Tryba M**. Sucralfate versus antacids or H₂-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate. *Crit Care Med* 1991; **19**: 942-949
- 28 **Azevedo JR**, Soares MG, Silva G, Palacio G. Prevention of stress ulcer bleeding in high risk patients. Comparison of three drugs. *Crit Care Med* 1999; **27**: A145
- 29 **Jung R**, MacLaren R. Proton-pump inhibitors for stress ulcer prophylaxis in critically ill patients. *Ann Pharmacother* 2002; **36**: 1929-1937
- 30 **Levy MJ**, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. *Dig Dis Sci* 1997; **42**: 1255-1259
- 31 **Laine LA**, Margolis B, Bagin RG, Conrad S, Gabrielly A, Quattrin A, Heta J, Frank W, Rock J, Hepburn B, Laurie L. Double-blind trial of omeprazole immediate release oral suspension (OME-IR SUSP) vs. intravenous cimetidine (IV CIM) for prevention of upper gastrointestinal (UGI) bleeding in critically ill patients. *Gastroenterology* 2004; **126**: A-77
- 32 **Daley RJ**, Rebuck JA, Welage LS, Rogers FB. Prevention of stress ulceration: current trends in critical care. *Crit Care Med* 2004; **32**: 2008-2013
- 33 **Spirit MJ**. Stress-related mucosal disease: risk factors and prophylactic therapy. *Clin Ther* 2004; **26**: 197-213
- 34 **Devlin JW**. Treatment options and formulary considerations in the management of acid suppression in critically ill patients. Introduction. *Am J Health Syst Pharm* 2005; **62**: S2-S3
- 35 **Shuman RB**, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. *Ann Intern Med* 1987; **106**: 562-567
- 36 **Zheng RN**. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. *World J Gastroenterol* 2009; **15**: 990-995
- 37 **Fasseas P**, Leybishkis B, Rocca G. Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by early repeat endoscopy. *Int J Clin Pract* 2001; **55**: 661-664
- 38 **Lanas A**. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications. *Postgrad Med* 2005; **117**: 23-28, 31
- 39 **Soylu A**, Dolapcioglu C, Dolay K, Ciltas A, Yasar N, Kalayci M, Alis H, Sever N. Endoscopic and histopathological evaluation of acute gastric injury in high-dose acetaminophen and nonsteroidal anti-inflammatory drug ingestion with suicidal intent. *World J Gastroenterol* 2008; **14**: 6704-6710
- 40 **Rivkin K**, Lyakhovetskiy A. Treatment of nonvariceal upper gastrointestinal bleeding. *Am J Health Syst Pharm* 2005; **62**: 1159-1170
- 41 **Olsen KM**. Use of acid-suppression therapy for treatment of non-variceal upper gastrointestinal bleeding. *Am J Health Syst Pharm* 2005; **62**: S18-S23
- 42 **Celiński K**, Cichoz-Lach H, Madro A, Słomka M, Kasztelan-Szczerbińska B, Dworżański T. Non-variceal upper gastrointestinal bleeding--guidelines on management. *J Physiol Pharmacol* 2008; **59** Suppl 2: 215-229
- 43 **Khilnani N**, Hussain N. Gastrointestinal bleeding. *Emerg Med* 2005; **37**: 27-32
- 44 **Manning-Dimmitt LL**, Dimmitt SG, Wilson GR. Diagnosis of gastrointestinal bleeding in adults. *Am Fam Physician* 2005; **71**: 1339-1346
- 45 **Green RM**, Flamm S. AGA technical review on the evaluation of liver chemistry tests. *Gastroenterology* 2002; **123**: 1367-1384
- 46 **Fudge KA**, Moore KA, Schneider DN, Sherrin TP, Wellman GS. Change in prescribing patterns of intravenous histamine₂-receptor antagonists results in significant cost savings without adversely affecting patient care. *Ann Pharmacother* 1993; **27**: 232-237
- 47 **Heidelbaugh JJ**, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. *Am J Gastroenterol* 2006; **101**: 2200-2205
- 48 **Estruch R**, Pedrol E, Castells A, Masanés F, Marrades RM, Urbano-Márquez A. Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. *Scand J Gastroenterol* 1991; **26**: 819-826
- 49 **Qadeer MA**, Richter JE, Brotman DJ. Hospital-acquired gastrointestinal bleeding outside the critical care unit: risk factors, role of acid suppression, and endoscopy findings. *J Hosp Med* 2006; **1**: 13-20
- 50 **Beejay U**, Wolfe MM. Acute gastrointestinal bleeding in the intensive care unit. The gastroenterologist's perspective. *Gastroenterol Clin North Am* 2000; **29**: 309-336
- 51 **Netzer P**, Gaia C, Sandoz M, Huluk T, Gut A, Halter F, Hüslér J, Inauen W. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours. *Am J Gastroenterol* 1999; **94**: 351-357

- 52 **Wirth SM**, Macaulay TE, Winstead PS, Smith KM. Stress-related mucosal disease: considerations of current medication prophylaxis. *Orthopedics* 2007; **30**: 1010-1014
- 53 **Sesler JM**. Stress-related mucosal disease in the intensive care unit: an update on prophylaxis. *AACN Adv Crit Care* 2007; **18**: 119-126; quiz 127-128
- 54 **Devlin JW**, Claire KS, Dulchavsky SA, Tyburski JG. Impact of trauma stress ulcer prophylaxis guidelines on drug cost and frequency of major gastrointestinal bleeding. *Pharmacotherapy* 1999; **19**: 452-460
- 55 **Hopefl A**. Rational use of parenteral proton pump inhibitors. *Hosp Pharm* 2001; **36**: 344-350
- 56 **Olsen KM**, Devlin JW. Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. *Aliment Pharmacol Ther* 2008; **28**: 326-333
- 57 **Wohlt PD**, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. *Ann Pharmacother* 2007; **41**: 1611-1616
- 58 **Zink DA**, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. *Aliment Pharmacol Ther* 2005; **21**: 1203-1209
- 59 **Laheij RJ**, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004; **292**: 1955-1960
- 60 **Yang YX**, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. *JAMA* 2006; **296**: 2947-2953
- 61 **Dial S**, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004; **171**: 33-38
- 62 **Cunningham R**, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. *J Hosp Infect* 2003; **54**: 243-245
- 63 **Erstad BL**, Camamo JM, Miller MJ, Webber AM, Fortune J. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center. *Crit Care Med* 1997; **25**: 1678-1684
- 64 **Liberman JD**, Whelan CT. Brief report: Reducing inappropriate usage of stress ulcer prophylaxis among internal medicine residents. A practice-based educational intervention. *J Gen Intern Med* 2006; **21**: 498-500
- 65 **Khudair IF**, Sadik ND, Hanssens YI. Prescribing pattern of acid suppressive medications for medical inpatients in a teaching hospital in Qatar. *Saudi Med J* 2009; **30**: 125-129
- 66 **Mayet AY**. Improper use of antisecretory drugs in a tertiary care teaching hospital: an observational study. *Saudi J Gastroenterol* 2007; **13**: 124-128

S- Editor Wang JL L- Editor Hughes D E- Editor Zheng XM

Acknowledgments to reviewers of World Journal of Gastrointestinal Pharmacology and Therapeutics

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Gastrointestinal Pharmacology and Therapeutics*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

Takayuki Yamamoto, MD, PhD, Inflammatory Bowel Disease Center, Yokkaichi Social Insurance Hospital, 10-8 Hazuyamacho, Yokkaichi, Mie 510-0016, Japan

Giedrius Barauskas, Professor, Department of Surgery, Kaunas University of Medicine, Kaunas, LT-50009, Lithuania

Frank C Mao, Professor, Department of Veterinary Medicine, National Chung Hsing University, 250 Kuo Kuang Road, Taichung 40227, Taiwan, China

Luca Elli, MD PhD, Centro per la Prevenzione e Diagnosi della Malattia Celiaca, Fondazione IRCCS Cà-Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, 20122 Milano, Italy

Rami Eliakim, Professor, Chief, Head, Department of Gastroenterology, Rambam Health Care Campus, Bat Galim, Haifa 30916, Israel

Tiberiu Hershcovici, Professor, Southern Arizona VA Health Care System, Section of Gastroenterology (111G-1), 3601 S. 6th Ave., Tucson, AZ 85723, United States

Ajith Kumar Siriwardena, Professor, Academic Hepatobiliary Unit, Manchester Academy of Health Sciences, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, United Kingdom

Ian Lawrance, PhD, Professor, School of Medicine and Pharmacology, University of Western Australia Director, Centre for Inflammatory Bowel Disease, Fremantle Hospital, T Block, Alma Street, Fremantle, WA 6160, Australia

Kristin Verbeke, PhD, Professor, Laboratory Digestion and Absorption, E462, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium

Giuseppe Brisinda, MD, Catholic Medical School, University Hospital "Agostino Gemelli", Largo Agostino Gemelli 8, Rome 00168, Italy

Yu-Jui Yvonne Wan, PhD, Professor, Liver Center, Room 4059 KL-SIC, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160-7417, United States

Katsuyuki Nakajima, PhD, President and CEO, Nakajima and Associates, Co., Ltd., 3-33-2, Minami-cho, Maebashi Gunma 371-0805, Japan

P Hemachandra Reddy, PhD, Neurogenetics Laboratory, Neuroscience Division, Oregon National Primate Research Center, West Campus, Oregon Health and Science University, 505 NW 185th Avenue, Beaverton, OR 97006, United States

Bo Shen, MD, FACC, Digestive Disease Institute-Desk A31, The Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, United States

Norihiro Furusyo, MD, PhD, Department of General Internal Medicine, Kyushu University Hospital, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

Takashi Kawai, MD, PhD, Professor, Endoscopy Center, Tokyo Medical University 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan



Events Calendar 2011

January 14-15, 2011

AGA Clinical Congress of
Gastroenterology and Hepatology:
Best Practices in 2011, Loews Miami
Beach Hotel, Miami, FL,
United States

January 27, 2011

Symposium of the Swiss Society
of Pharmacology and Toxicology,
Advances in Pharmacology-
Psychopharmacology, Bern,
Switzerland

February 17-20, 2011

APASL 2011 - The 21st Conference
of the Asian Pacific Association for
the Study of the Liver, Bangkok,
Thailand

February 26-March 01, 2011

Canadian Digestive Diseases Week,
Westin Bayshore, Vancouver, British
Columbia, Canada

March 02-05, 2011

American Society for Clinical

Pharmacology and Therapeutics
2011 Annual Meeting, Dallas, TX,
United States

March 22-24, 2011

11th South East Asian Western
Pacific Regional Meeting of
Pharmacologists in conjunction
with the 84th Annual Meeting of the
Japanese Pharmacological Society,
Yokohama, Japan

March 24, 2011

Asia Pharma R&D Leaders 2011-the
largest and premier pharma R&D
summit in China, Shanghai, China

April 06-08, 2011

Third Latin American Symposium
on Gastrointestinal Oncology -
Chilean Foundation for Oncology
Development Joint Symposium,
Vina Del Mar, Chile

April 20-23, 2011

9th International Gastric Cancer
Congress, COEX, World Trade
Center, Samseong-dong, Gangnam-
gu, Seoul 135-731, South Korea

May 22-25, 2011

2011 American Academy of
Veterinary Pharmacology &
Therapeutics 17th Biennial
Symposium, 610 Langdon Street,
Madison, WI, United States

May 24-27, 2011

Meeting joint between CSPT and the
Canadian Society for Pharmaceutical
Sciences, the Controlled Release
Society and the Natural Health
Products Research Society of
Canada, Montreal, Quebec, Canada

June 26-29, 2011

10th European Association for
Clinical Pharmacology and
Therapeutics Congress, Budapest,
Hungary

September 11-13, 2011

40th Annual Meeting of American
College of Clinical Pharmacology,
Crowne Plaza Chicago O'Hare
Hotel, Chicago, IL, United States

October 02-06, 2011

12th International Congress of
Therapeutic Drug Monitoring

& Clinical Toxicology, Stuttgart,
Germany

October 06-07, 2011

IV InterAmerican Oncology
Conference: Current Status and
Future of Anti-Cancer Targeted
Therapies, Buenos Aires, Argentina

November 11-12, 2011

Falk Symposium 180, IBD 2011:
Progress and Future for Lifelong
Management, 1-12-33 Akasaka,
Minato-ku, Tokyo 107-0052, Japan

December 01-04, 2011

International Symposium On Ocular
Pharmacology And Therapeutics,
Hilton Vienna, Vienna, Austria

December 04-07, 2011

Perth 2011 joint Meeting between
the Australian Physiological Society,
the Australian Society of Clinical
and Experimental Pharmacologists
and the High Blood Pressure
Research Council of Australia, Perth
Convention Centre, Perth. WA,
Australia



INSTRUCTIONS TO AUTHORS

GENERAL INFORMATION

World Journal of Gastrointestinal Pharmacology and Therapeutics (*World J Gastrointest Pharmacol Ther*, *WJGPT*, online ISSN 2150-5349, DOI: 10.4292), is a bimonthly, open-access (OA), peer-reviewed journal supported by an editorial board of 188 experts in gastrointestinal pharmacology and therapeutics from 36 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJGPT* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article *via* online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJGPT* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJGPT* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles,

thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

Aims and scope

The major task of *WJGPT* is to rapidly report the most recent results in basic and clinical research on gastrointestinal pharmacology & therapeutics, including the effects of drugs on the gastrointestinal, pancreatic and hepatobiliary systems, particularly with relevance to clinical practice. *WJGPT* accepts papers on the following aspects related to gastroenterology or hepatology: (1) Clinical pharmacological research articles on specific drugs, concerning with pharmacodynamics, pharmacokinetics, toxicology, clinical trial, drug reactions, drug metabolism and adverse reaction monitoring, *etc*; (2) Research progress of clinical pharmacology; (3) Introduction and evaluation of new drugs; (4) Experiences and problems in applied therapeutics; (5) Research and introductions of methodology in clinical pharmacology; and (6) Guidelines of clinical trial. Specifically, this journal welcome research and review articles associated with both Western medicine and Chinese herbs as well as their combinations in basic and clinical application.

Columns

The columns in the issues of *WJGPT* will include: The columns in the issues of *WJGPT* will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systemically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in gastrointestinal pharmacology & therapeutics; (9) Brief Articles: To briefly report the novel and innovative findings in gastrointestinal pharmacology & therapeutics; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in *WJGPT*, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of gastrointestinal pharmacology & therapeutics; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in gastrointestinal pharmacology & therapeutics.

Name of journal

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

ISSN 2150-5349 (online)

Indexing/abstracting

PubMed Central, PubMed, Digital Object Identifier, and Directory of Open Access Journals.

Published by

Baishideng Publishing Group Co., Limited

SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Redit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJGPT* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: http://www.icmje.org/ethical_4conflicts.html.

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the

understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2150-5349office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS (http://www.wjgnet.com/2150-5349/g_info_20100315084234.htm) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to wjgpt@wjgnet.com, or by telephone: +86-10-85381891. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

Title page

Title: Title should be less than 12 words.

Running title: A short running title of less than 6 words should be provided.

Authorship: Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Au-

thors should meet conditions 1, 2, and 3.

Institution: Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

Author contributions: The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

Supportive foundations: The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

Correspondence to: Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

Telephone and fax: Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381891 Fax: +86-10-85381893

Peer reviewers: All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJGPT*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g. 6.92 ± 3.86 vs 3.61 ± 1.67 , $P < 0.001$; CONCLUSION (no more than 26 words).

Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: http://www.wjgnet.com/2150-5349/g_info_list.htm.

Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

Notes in tables and illustrations

Data that are not statistically significant should not be noted. ^a*P* < 0.05, ^b*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, ^c*P* < 0.05 and ^d*P* < 0.01 are used. A third series of *P* values can be expressed as ^e*P* < 0.05 and ^f*P* < 0.01. Other notes in tables or under illustrations should be expressed as ¹F, ²F, ³F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

REFERENCES

Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated

Instructions to authors

with increased intestinal permeability^[1,2]". If references are cited directly in the text, they should be put together within the text, for example, "From references^[19,22-24], we know that...".

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

Format

Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diar-rhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache*

2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

Books

Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfeide AM. Adolescent pregnancy. 2nd ed. Wiecezorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. *Emerg Infect Dis* serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

Statistical data

Write as mean \pm SD or mean \pm SE.

Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as χ^2 (in Greek), related coefficient as *r* (in italics), degree of freedom as *ν* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose) 6.4 \pm 2.1 mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μ g/L; CO₂ volume fraction, 50 mL/L CO₂, not 5% CO₂; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: http://www.wjgnet.com/2150-5349/g_info_20100315090437.htm.

Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbrevi-

ated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, etc.

Biology: *H. pylori*, *E. coli*, etc.

Examples for paper writing

Editorial: http://www.wjgnet.com/2150-5349/g_info_20100315084421.htm

Frontier: http://www.wjgnet.com/2150-5349/g_info_20100315084456.htm

Topic highlight: http://www.wjgnet.com/2150-5349/g_info_20100315084631.htm

Observation: http://www.wjgnet.com/2150-5349/g_info_20100315084740.htm

Guidelines for basic research: http://www.wjgnet.com/2150-5349/g_info_20100315084855.htm

Guidelines for clinical practice: http://www.wjgnet.com/2150-5349/g_info_20100315085009.htm

Review: http://www.wjgnet.com/2150-5349/g_info_20100315085358.htm

Original articles: http://www.wjgnet.com/2150-5349/g_info_20100315085528.htm

Brief articles: http://www.wjgnet.com/2150-5349/g_info_20100315085703.htm

Case report: http://www.wjgnet.com/2150-5349/g_info_20100315085812.htm

Letters to the editor: http://www.wjgnet.com/2150-5349/g_info_20100315085932.htm

Book reviews: http://www.wjgnet.com/2150-5349/g_info_20100315090039.htm

Guidelines: http://www.wjgnet.com/2150-5349/g_info_20100315090116.htm

SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJGPT*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

Editorial Office

World Journal of Gastrointestinal Pharmacology and Therapeutics

Editorial Department: Room 903, Building D,
Ocean International Center,
No. 62 Dongsihuan Zhonglu,
Chaoyang District, Beijing 100025, China
E-mail: wjgpt@wjgnet.com
<http://www.wjgnet.com>
Telephone: +86-10-8538-1891
Fax: +86-10-8538-1893

Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

Copyright assignment form

Please download a Copyright assignment form from http://www.wjgnet.com/2150-5349/g_info_20100315090344.htm.

Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: http://www.wjgnet.com/2150-5349/g_info_20100315090255.htm.

Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

Links to documents related to the manuscript

WJGPT will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

Publication fee

WJGPT is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, original articles, book reviews and letters to the editor are published free of charge.